The Swedish executive who sold his last company to Teleflex for $600 million, then walked into a Tempe, Arizona office to run a firm whose only product is a collagen tile a surgeon sews into a brain tumor cavity before closing the skull.
There is a moment, in a specific kind of neurosurgery, when the tumor has been removed and the cavity is still open. In that moment, the surgeon can either close the skull and hand the patient off for external beam radiation weeks later, or reach for a small square of bioresorbable collagen with radioactive Cesium-131 seeds embedded in it. Per Langoe would prefer the second option.
Langoe runs GT Medical Technologies, the company that makes that square. It is called GammaTile. It is FDA-cleared for newly diagnosed and recurrent malignant intracranial neoplasms. It has been placed in roughly 2,000 patients as of August 2025. And its CEO, until February 2024, was somebody else entirely.
Langoe replaced Matt Likens, the founding CEO who retired in January 2024. The setup - a science company transitioning from its founding chief to a commercial operator - is a familiar one in medtech. Founding CEOs get the FDA clearance. The second CEO gets the invoice.
The invoice, in Langoe's case, is roughly 200 US institutions that could plausibly do the procedure. GT Medical is in about 120 of them. That leaves a ceiling and a floor visible from the same window. Most CEOs would find this claustrophobic. Langoe, whose last company sold radiation-adjacent products to a similarly narrow group of specialists, appears to find it clarifying.
If you use GammaTile, you can introduce it immediately after you have resected the tumor, so the patient gets a high-dose radiation boost.— Per Langoe to MedTech Dive, 2024
One of the more interesting sentences Langoe has said in public: "There might be around 200 institutions in the U.S. in total that could potentially do these procedures. And we are right now in about 100, 120 institutions." Read one way, that is a limitation. Read another, it is a moat with a countdown timer.
GammaTile is not a mass-market device. It requires a neurosurgeon comfortable with implanting radioactive material and a radiation oncologist willing to sign off. That combination exists at roughly 200 US institutions. GT Medical is in the majority of them. Langoe's job is the last third - and, more importantly, deepening usage inside the hospitals already saying yes.
Langoe's career reads like a map of Swedish life sciences with one American colon. He grew up in Sweden, earned a BSc in International Business Studies and then an MSc in Business Studies from Uppsala University, and started at Pharmacia Corporation - the sprawling Swedish pharmaceutical firm that later merged with Pfizer. From there: Q-Med, the Swedish company best known for Restylane. Then Galderma. Then Nestle Skin Health.
The through-line is not the products, which range from hyaluronic-acid fillers to prescription dermatology. It is the buyer. Langoe has spent most of his career selling technical products into rooms where the person listening has an MD after their name and a schedule that does not move for salespeople.
In roughly the mid-2010s he co-founded Palette Life Sciences with two partners, Travis and Ole. Palette was fully integrated - clinical trials, regulatory work, commercial launch, all inside the same company. Its flagship product, a hydrogel spacer used in radiation oncology to protect healthy tissue near the prostate, was the kind of adjunctive tool that either becomes standard of care or does not. It did. Teleflex acquired Palette in 2023 for $600 million.
Seven months later, Langoe was in Tempe running a company with one product, an FDA clearance, a founding-CEO retirement, and a runway problem. The Palette playbook - narrow specialty, radiation oncologists, adjunctive-not-replacement - is essentially the GammaTile playbook. This is not a coincidence. This is what a second act looks like when the first one worked.
There might be around 200 institutions in the U.S. in total that could potentially do these procedures. And we are right now in about 100, 120 institutions.— Per Langoe, on the visible ceiling of his market
Ask Langoe about competitive advantage and he does not describe GammaTile's radioisotope, the specific activity of Cesium-131, or the collagen chemistry. He describes what happens in the ninety minutes after tumor removal. External beam radiation, historically the standard, requires the patient to heal from surgery, come back for planning, then return for daily fractions. GammaTile is placed in the cavity as the surgeon closes. The gap between resection and radiation collapses from weeks to zero.
This is a workflow claim, not a product claim, and it is why Langoe talks about "partnering with healthcare providers to understand workflow integration and minimize clinical practice disruptions." The sentence is boring by design. The strategy underneath it is not.
His other repeated theme is vertical manufacturing integration. GT Medical closed a $100M Series E in June 2026, and Langoe has been explicit about spending some of it on North American supply chain security. When your product contains a regulated radioisotope with a 9.7-day half-life, the cost of a supply hiccup is measured in patient outcomes, not gross margin. He does not want to find out how expensive.
The third leg is BRIDGES, the trial GT Medical is running for newly diagnosed glioblastoma. Glioblastoma is the tumor that killed Beau Biden and John McCain and, statistically, most patients diagnosed with it. If GammaTile works in newly diagnosed GBM, the label expands, the addressable population grows, and the 200-hospital ceiling becomes something like a 200-hospital funnel.
Both his degrees, undergraduate and graduate, come from the same building in the same city: Uppsala University, Sweden.
He runs a medical device company from Tempe but chairs the board of ProstaLund AB in Sweden. His calendar clears customs.
His last company was named after a painter's palette. His current one is named after a Greek letter. Both handle radiation adjunctively.
He co-founded Palette with two partners, Travis and Ole. It is a small enough origin story to fit in a coffee shop.
The Series E closed at $100M and was described as oversubscribed. In a 2026 medtech market, "oversubscribed" is not a filler word.
He is the CEO of GT Medical Technologies, the Arizona medical device company behind GammaTile, an FDA-cleared brain tumor radiation therapy.
He co-founded Palette Life Sciences, serving as its President and CEO until Teleflex acquired the company for $600 million in 2023.
He earned both a BSc and an MSc in Business Studies and Economics from Uppsala University in Sweden.
February 2024. He succeeded founding CEO Matt Likens, who had retired the prior month.
A bioresorbable collagen tile embedded with Cesium-131 seeds, placed by a surgeon into the brain tumor cavity to deliver targeted radiation the moment the tumor is removed.